公司简介
公司的长期目标是发展一系列治疗胰腺癌等复发难治恶性肿瘤的TCR产品,识别共享基因突变和肿瘤新生抗原,将细胞治疗产品做到个性化与通用相结合,缩短细胞治疗产品制备周期,提高细胞治疗的有效性和可及性。
Shanghai Bintie Biotechnology Co., Ltd. is a cutting-edge clinical-stage biotech company leading the way in developing a new type of immunocyte preparation that specifically targets solid tumors. The company's founder commands international influence in the field of tumor immunology, with several immunotherapy drugs, originally developed in the United States, currently in the clinical trial stage.
The company's unwavering long-term objective is to spearhead the development of a pioneering series of TCR products to effectively address recurrent and refractory malignant tumors, such as pancreatic cancer. Our mission encompasses the identification of TCRs that recognize shared cancer driver gene mutations and tumor neoantigens, the integration of personalized and universal cell therapy products, as well as the streamlining of the preparation cycle of cell therapy products, all with the ultimate goal of enhancing the effectiveness and accessibility of cell therapy.